Prognostic factors for survival after bronchoscopic intervention in patients with airway obstruction due to primary pulmonary malignancy

Bo-Guen Kim†, Beomsu Shin‡, Boksoon Chang³, Hojoong Kim¹ and Byeong-Ho Jeong¹*  

Abstract  
Background: Malignant central airway obstruction (MCAO) occurs in 20–30% of patients with primary pulmonary malignancy. Although bronchoscopic intervention is widely performed to treat MCAO, little data exist on the prognosis of interventional bronchoscopy. Therefore, we evaluated the clinical outcomes and prognostic factors of bronchoscopic interventions in patients with MCAO due to primary pulmonary malignancy.  
Methods: This retrospective study was conducted at a university hospital and included 224 patients who received interventional bronchoscopy from 2004 to 2017, excluding patients with salivary gland-type tumor. A multivariable Cox proportional hazard regression analysis was used to identify independent prognostic factors associated with survival after the first bronchoscopic intervention.  
Results: Among 224 patients, 191 (85.3%) were males, and the median age was 63 years. The most common histological type of malignancy was squamous cell carcinoma (71.0%). Technical success was achieved in 93.7% of patients. Acute complications and procedure-related death occurred in 15.6 and 1.3% of patients, respectively. The median survival time was 7.0 months, and survival rates at one year and two years were 39.7 and 28.3%, respectively. Poor survival was associated with underlying chronic pulmonary disease, poor performance status, extended lesion, extrinsic or mixed lesion, and MCAO due to disease progression and not receiving adjuvant treatment after bronchoscopic intervention.  
Conclusions: Interventional bronchoscopy could be a safe and effective procedure for patients who have MCAO due to primary pulmonary malignancy. In addition, we found several prognostic factors for poor survival after intervention, which will help clinicians determine the best candidates for bronchoscopic intervention.  
Keywords: Airway obstruction, Lung cancer, Bronchoscopic intervention

* Correspondence: myacousticlung@gmail.com  
†Bo-Guen Kim and Beomsu Shin contributed equally to this work.  
‡Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, South Korea  
Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
The development of new anti-cancer drugs and imaging techniques, such as low-dose computed tomography (CT), has improved the survival rate in patients with primary pulmonary malignancy [1–3]. However, lung cancer is still one of the most fatal malignancies, and many patients die of complications related to disease progression [4, 5]. In particular, central airway obstruction is one of the major complications and causes hemoptysis, atelectasis, and obstructive pneumonia. Eventually, these patients experience disability in daily activities and are at increased risk of repeated hospitalization for respiratory failure [6].

Malignant central airway obstruction (MCAO), which is defined as ≥50% occlusion of the cross-sectional area of the central airway, occurs in 20–30% of patients with primary pulmonary malignancy caused by endoluminal metastasis or extrinsic compression of bulky lymphadenopathy [7]. In patients with MCAO, surgical interventions are rarely indicated for tumors obstructing the trachea and main carina [8]. The effects of chemotherapy or radiation therapy may take a long time to relieve the MCAO [9]. However, bronchoscopic interventions, such as mechanical debulking, laser cauterization, and stent placement, can immediately relieve symptoms related to airway obstruction and improve quality of life [10]. Previous studies have demonstrated the efficacy of this procedure in decreasing the frequency and severity of dyspnea and improving other clinically relevant endpoints [8, 11–13]. In multicenter studies, more than 90% success rates and low complication rates have been confirmed following interventional bronchoscopy in patients with MCAO [14]. However, to the best of our knowledge, few articles have reported the prognostic factors associated with survival after bronchoscopic intervention.

Therefore, the purpose of our study was to evaluate the clinical outcomes and prognostic factors of bronchoscopic interventions in patients with MCAO due to primary pulmonary malignancy.

Methods
Patients
The characteristics of airway obstruction were assessed by CT and, when possible, flexible bronchoscopy. MCAO was defined as ≥50% occlusion of the cross-sectional area of the central airway (from trachea to lobar bronchus) on CT or bronchoscopic findings [14]. From January 2004 to December 2017, interventional bronchoscopy was performed in 295 patients with MCAO due to primary pulmonary malignancy at Samsung Medical Center, a university-affiliated hospital in South Korea. Patients with salivary gland-type tumors (n = 71), such as adenoid cystic carcinoma, mucoepidermoid carcinoma, and epithelial-myoepithelial carcinoma, were excluded from this study because of their biological differences and good prognosis due to being distinguished from non-small cell and small cell lung cancer [15–18]. Finally, total 224 patients were analyzed.

The Institutional Review Board of Samsung Medical Center approved this study (2019–03-002) and waived informed consent due to its retrospective nature.

Airway interventional techniques
Interventional bronchoscopy was performed according to standard techniques [19, 20]. Details of airway interventional techniques were described in previous reports [21]. In short, after induction of general anesthesia and intubation with a rigid bronchoscope tube (Bryan Co., Woburn, MA, USA or Karl-Storz, Tuttingen, Germany), various combinations of airway intervention techniques (mechanical debulking, laser, and insertion of silicone stents) were used depending on the characteristics of airway obstruction. Any intraluminal mass was removed mechanically using rigid bronchoscope tubes and cauterized by using neodymium-doped yttrium aluminum garnet laser (LaserSonics, Milpitas, CA, USA) or diode laser (BioLtec, Ceralas*, Germany). Additionally, if there was an extrinsic compression or high likelihood of rapid tumor ingrowth, a silicone stent (Natural stent [M1S Co., Seoul, Korea] or Dumon stent [Novatech, La Ciotat, France]) was inserted to maintain airway patency [21].

Technical success was assessed based on the anatomic criteria of reopening of the airway lumen to > 50% of the normal cross-sectional area and connection to a viable area in the distal lung on bronchoscopy [14]. If a physician successfully reopened a proximal airway but discovered distal lesions occluding all segmental or subsegmental levels, we classified this as a technical failure [14].

Data collection
We retrospectively analyzed the medical data from 224 patients using the following data: demographic characteristics, histological type of malignancy, bronchoscopic findings (site of lesion, type of obstruction, and severity and length of stenosis), pre- and post-procedure treatment modalities, airway intervention techniques, procedure-related complications, and survival period.

The following terms were defined identically to our previous report [21]. Poor performance was defined as ≥ American Society of Anesthesiologists (ASA) physical status class 3, which means severe systemic disease with functional limitations [22]. We evaluated the severity of airway stenosis using the Myer-Cotton stenosis grading
system: Grade I, ≤50% luminal stenosis; Grade II, 51–70% luminal stenosis; Grade III, 71–99% luminal stenosis; Grade IV, no lumen [23]. Respiratory distress was defined as decrease in oxygen saturation or worsened dyspnea after the procedure and need for additional oxygen for at least 24 h [21]. We defined excessive bleeding as procedure-related bleeding in which blood transfusion or escalated care was needed [21]. Because most patients with MCAO due to primary pulmonary malignancy were already far advanced at the time of the first bronchoscopic intervention, the status of malignancy was defined as follows [21]. The first category was when the MCAO was discovered along with the initial diagnosis of primary pulmonary malignancy that had never been treated, and the second one was when the MCAO was caused by progression of a primary pulmonary malignancy that had already been treated with anti-cancer treatment. Finally, we investigated whether the patients had received any adjuvant therapy after the bronchoscopic intervention.

**Statistical analysis**

Data are presented as number (%) for categorical variables and median (interquartile range [IQR]) for continuous variables. The Kaplan-Meier method was used to estimate the overall survival rate after the first bronchoscopic intervention. A multivariable Cox proportional hazard regression analysis with backward stepwise selection, with \( P < 0.05 \) for entry of variables, and \( P > 0.10 \) for removal of variables were used to identify independent prognostic factors associated with overall survival. Statistical differences were considered significant at \( P < 0.05 \). All statistical analyses were performed using SPSS software (IBM SPSS Statistics ver. 25, Chicago, IL, USA).

**Results**

**Baseline characteristics**

The characteristics of the study population are described in Table 1. Among 224 patients, 191 (85.3%) were male, and the median age was 63 (IQR, 56–69) years. Of these patients, 176 (78.6%) had a smoking history of median 40 (IQR, 30–50) pack-year. The most common comorbidity was chronic pulmonary disease (20.1%). Sixty-eight patients (30.4%) had a poor performance status, and intubation was required before the intervention in 27 (12.1%) patients. Squamous cell carcinoma (71.0%) was the most common histological type of malignancy.

Characteristics of the MCAO site are described in Table 2. Among 224 patients, 173 (77.2%) had a single-site obstruction, while 51 (22.8%) had obstructions at two or more sites. Endobronchial, mixed, and extrinsic types of obstructions were identified in 125 (55.8%), 80 (35.7%), and 19 (8.5%) patients, respectively. Most patients (76.8%) had ≥71% obstruction of the cross-sectional area (Myer and Cotton Grade III or IV). The median length of stenosis was 27 mm (IQR, 18–35 mm). Some patients (2.2%) had a fistula between the trachea and esophagus.

**Treatment modalities and complications**

Treatment-related information is detailed in Table 3. There was an average of 0.5 months (IQR, 0.2–1.3 months) from diagnosis of MCAO to the first bronchoscopic intervention. The median procedure time was 35 min (IQR, 28–45 min). Mechanical debulking was performed in patients who had endobronchial and mixed lesions; additional procedures, such as stent insertion (50.4%), laser cautery (31.7%), and ballooning (10.3%), were used in combination according to the characteristics of the individual lesions. During the study

| Table 1 Baseline characteristics |
|----------------------------------|
| Variables                        |
| Age, years                       |
| Sex, male                        |
| Body mass index, kg/m²           |
| Smoking                          |
| Chronic pulmonary disease        |
| Diabetes mellitus                |
| Congestive heart disease         |
| Chronic liver disease            |
| Chronic kidney disease           |
| Cerebrovascular disease          |
| Poor performance status          |
| Intubation due to respiratory failure before intervention |
| Histological type of malignancy  |
| Non-small cell carcinoma         |
| Squamous cell carcinoma          |
| Adenocarcinoma                   |
| Others                           |
| Small cell carcinoma             |

Data are presented as \( n \) (%) or the median (interquartile range)

*Excluding never smoker and 11 patients with ex-smoker who had no information*

*American Society of Anesthesiologists (ASA) physical status class ≥3 means severe systemic disease with functional limitation*

*Poorly differentiated \( n = 7 \), large cell neuroendocrine carcinoma \( n = 3 \), pleomorphic carcinoma \( n = 3 \), lymphoepithelioma-like carcinoma \( n = 1 \), sarcomatoid carcinoma \( n = 1 \), basalioid squamous cell carcinoma \( n = 1 \)
period, 55 (24.6%) patients received two or more bronchoscopic interventions. Overall, technical success was achieved in 93.7%. Of the 96 (42.9%) patients who were diagnosed with MCAO during initial diagnosis of malignancy, 27 (12.1%) did not receive adjuvant treatment after interventional bronchoscopy because of poor general condition (n = 23) or rejection of additional treatment by the patient (n = 4). Of 128 (57.1%) patients diagnosed with MCAO as a part of the disease progression of malignancy, 42 (18.7%) did not receive adjuvant treatment after interventional bronchoscopy due to poor general condition (n = 32), rejection of additional treatment (n = 7), or lack of further treatment options (n = 3).

Acute complications occurred in 33 (17%) patients, comprising excessive bleeding (n = 14), respiratory distress (n = 18), and pneumothorax (n = 3). Three procedure-related deaths were recorded due to excessive bleeding (n = 2) and tension pneumothorax (n = 1). Although chronic complications occurred in 48 (21.4%) patients, including granulation tissue overgrowth (n = 26), restenosis (n = 20), mucostasis (n = 16), and stent migration (n = 3), most complications were manageable with additional procedures.

Survival and prognosis

Table 4 shows the independent prognostic factors related to mortality based on univariate and multivariate

---

**Table 2 Bronchoscopic findings**

| Variables                          | N = 224 |
|-----------------------------------|---------|
| **Site of lesion**                |         |
| Single lesion                     | 173 (77.2) |
| Trachea                           | 44 (19.6) |
| Left main bronchus                | 45 (20.1) |
| Right main bronchus               | 37 (16.5) |
| Right bronchus intermedius        | 20 (8.9) |
| Lobar bronchus                    | 27 (12.1) |
| Extended lesion                   | 51 (22.8) |
| Trachea and each or both bronchi  | 26 (11.6) |
| Both bronchi                      | 25 (11.2) |
| **Type of obstruction**           |         |
| Endobronchial lesion              | 125 (55.8) |
| Extrinsic compression             | 19 (8.5) |
| Mixed lesion                      | 80 (35.7) |
| **Severity of stenosis (Myer and Cotton grade)** |         |
| Grade II                          | 52 (23.1) |
| Grade III                         | 97 (43.4) |
| Grade IV                          | 75 (33.5) |
| **Length of MCAO, mm**            | 27 (18–35) |
| **Combined fistula from trachea to esophagus** | 5 (2.2) |

Data are presented as n (%) or the median (interquartile range). MCAO, malignant central airway obstruction.

* Categorization based on the percentage of reduction in cross-sectional area. Grade 1, ≤ 50% lumenal stenosis; Grade II, 51–70% lumenal stenosis; Grade III, 71–99% lumenal stenosis; Grade IV, no lumen.

**Table 3 Treatment modalities and complications**

| Variables                                                | N = 224 |
|----------------------------------------------------------|---------|
| **Time interval from diagnosis of MCAO to treatment, months** | 0.5 (0.2–1.3) |
| **Procedure time, min**                                  | 35 (28–45) |
| **Treatment modalities**                                 |         |
| Mechanical debulking                                      | 205 (91.5) |
| Silicone stent                                            | 113 (50.4) |
| Tube stent                                               | 96 (42.9) |
| Y stent                                                  | 17 (7.6) |
| Laser                                                    | 71 (31.7) |
| Ballooning                                               | 23 (10.3) |
| **Number of interventional bronchoscopies**              |         |
| 1                                                        | 169 (75.4) |
| ≥ 2                                                      | 55 (24.6) |
| **Technical failure**                                    | 14 (6.3) |
| **MCAO as initial diagnosis of malignancy**              |         |
| No adjuvant treatment after interventional bronchoscopy  | 27 (12.1) |
| Adjuvant radiation therapy                               | 44 (19.6) |
| Adjuvant chemotherapy                                     | 31 (13.8) |
| Adjuvant surgical resection                              | 19 (8.5) |
| **MCAO as disease progression of malignancy**            |         |
| No adjuvant treatment after interventional bronchoscopy  | 42 (18.8) |
| Adjuvant radiation therapy                               | 49 (21.9) |
| Adjuvant chemotherapy                                     | 56 (25.0) |
| Adjuvant surgical resection                              | 6 (2.7) |
| **Acute complications**                                  | 33 (17.0) |
| Respiratory distress                                     | 18 (8.0) |
| Excessive bleeding                                        | 14 (6.3) |
| Pneumothorax                                             | 3 (1.3) |
| Procedure-related death*                                  | 3 (1.3) |
| **Chronic complications**                                | 48 (21.4) |
| Granulation tissue overgrowth                            | 26 (11.6) |
| Restenosis                                               | 20 (8.9) |
| Mucostasis                                                | 16 (7.1) |
| Stent migration                                           | 3 (1.3) |

Data are presented as n (%) or the median (interquartile range). MCAO, malignant central airway obstruction.

 Patients could undergo more than one adjuvant treatment
 Patients could have one more complications

* Three patients died of excessive bleeding (n = 2) and tension pneumothorax (n = 1)
| Variable | Univariable Cox regression | Multivariable Cox regression |
|----------|----------------------------|-----------------------------|
|          | Unadjusted HR (95% CI)     | Adjusted HR (95% CI)        |
|          | P                          | P                           |
| **Host-related factors** |                               |                             |
| Age, years | 1.018 (0.997–1.039)         | 1.640 (1.082–2.488)         |
| Sex, male  | 1.192 (0.721–1.969)         | 0.529 (0.231–1.211)         |
| Body mass index, kg/m² | 0.936 (0.887–0.987)         | 0.529 (0.231–1.211)         |
| Smoking history |                               |                             |
| No        | Reference                   |                             |
| Yes       | 1.062 (0.709–1.589)         | 0.772                       |
| **Comorbidity** |                               |                             |
| Chronic pulmonary disease | 1.764 (1.135–2.740)         | 1.640 (1.082–2.488)         |
| Diabetes mellitus | 1.625 (0.989–2.670)         | 0.529 (0.231–1.211)         |
| Congestive heart disease | 0.719 (0.369–1.401)         | 0.529 (0.231–1.211)         |
| Chronic kidney disease | 0.458 (0.194–1.082)         | 0.529 (0.231–1.211)         |
| Chronic lung disease | 1.723 (0.488–6.081)         | 0.529 (0.231–1.211)         |
| Cerebrovascular disease | 0.616 (0.077–4.913)         | 0.529 (0.231–1.211)         |
| Poor performance status | 1.946 (1.276–2.968)         | 1.750 (1.206–2.540)         |
| Intubation due to respiratory failure before intervention | 0.881 (0.500–1.553) | 0.661 |
| **Histological type of malignancy** |                               |                             |
| Adenocarcinoma | Reference                   |                             |
| Squamous cell carcinoma | 1.075 (0.662–1.746)         | 0.769                       |
| Others | 1.306 (0.614–2.777)         | 0.489                       |
| Small cell carcinoma | 1.863 (0.750–4.627)         | 0.180                       |
| **Lesion-related factors** |                               |                             |
| Site of lesion |                               |                             |
| Single lesion | Reference                   |                             |
| Extended lesion | 1.399 (0.903–2.167)         | 1.545 (1.035–2.305)         |
| Type of obstruction |                               |                             |
| Endobronchial lesion | Reference                   |                             |
| Extrinsic compression | 2.525 (1.245–5.125)         | 2.119 (1.120–4.011)         |
| Mixed lesion | 2.555 (1.685–3.874)         | 2.388 (1.657–3.442)         |
| Severity of stenosis (Myer and Cotton grade) |               |                             |
| II and III | Reference                   | 2.388 (1.657–3.442)         |
| IV | 1.272 (0.887–1.824)         | 0.191                       |
| Length of MCAO | 1.002 (0.988–1.016)         | 0.787                       |
| Combined fistula | 0.487 (0.157–1.511)         | 0.213                       |
| **Disease status and adjuvant treatment-related factors** |                   |                             |
| MCAO as initial diagnosis with adjuvant treatment | Reference | Reference |
| MCAO as initial diagnosis without adjuvant treatment | 2.344 (1.318–4.169) | 2.370 (1.349–4.162) |
| MCAO as disease progression with adjuvant treatment | 2.122 (1.352–3.332) | 2.179 (1.413–3.359) |
| MCAO as disease progression without adjuvant treatment | 5.296 (3.142–8.926) | 5.099 (3.075–8.453) |

HR: hazard ratio; CI: confidential interval; MCAO: malignant central airway obstruction

- **Notes:**
  - a American Society of Anesthesiologists (ASA) physical status grade ≥ 3 means severe systemic disease with functional limitation
  - b Poorly differentiated (n = 7), large cell neuroendocrine carcinoma (n = 3), pleomorphic carcinoma (n = 3), lymphoepithelioma-like carcinoma (n = 1), sarcomatoid carcinoma (n = 1), basaloid squamous cell carcinoma (n = 1)
  - c Categorization based on the percentage of reduction in cross-sectional area. Grade 1, ≤ 50% luminal stenosis; Grade II, 51–70% luminal stenosis; Grade III, 71–99% luminal stenosis; Grade IV, no lumen
  - d Length of MCAO was defined as the sum of the length of the obstructive lesions more than grade II

---

*Kim et al. BMC Pulmonary Medicine (2020) 20:54*
Cox proportional hazard regressions. First, of the host-related factors, chronic pulmonary disease (adjusted hazard ratio [aHR], 1.640; 95% confidence interval [CI], 1.082–2.488; \(P = 0.020\)) and poor performance status (aHR, 1.750; 95% CI, 1.206–2.540; \(P = 0.003\)) were associated with poor survival. Second, of the lesion-related factors, an extended lesion was significantly associated with worse survival compared to a single lesion (aHR, 1.545; 95% CI, 1.035–2.305; \(P = 0.033\)). In addition, extrinsic compression (aHR, 2.119; 95% CI, 1.120–4.011; \(P = 0.021\)) and mixed lesions (aHR, 2.388; 95% CI, 1.657–3.442; \(P < 0.001\)) had a lower survival rate than endobronchial lesions. Finally, of the disease status and adjuvant treatment-related factors, patients with MCAO as disease progression without adjuvant treatment (aHR, 5.099; 95% CI, 3.075–8.453; \(P < 0.001\)) had the worst survival among all the patient groups. Patients who were diagnosed with MCAO during initial diagnosis but did not receive adjuvant treatment (aHR, 2.370; 95% CI, 1.349–4.162; \(P = 0.003\)) and patients identified as having MCAO during disease progression who did receive adjuvant treatments (aHR, 2.179; 95% CI, 1.413–3.359; \(P < 0.001\)) had similar worse prognoses than those diagnosed with MCAO during initial diagnosis who received adjuvant treatments.

The overall survival period had a median of 7.0 months; the one-year and two-year survival rates were 39.7 and 28.3%, respectively (Fig. 1a). Figure 1 also shows the overall survival after the first bronchoscopic intervention according to independent prognostic factors (existence of chronic pulmonary disease, performance status, site of lesion, type of obstruction, and detection time for MCAO with or without adjuvant treatment).

**Discussion**

In this study, technical success of interventional bronchoscopy was achieved in 93.7% of patients with MCAO due to primary pulmonary malignancy, and the procedure-related death rate was only 1.3%. An important point of our study is that we tried to identify the independent prognostic factors associated with survival after the first bronchoscopic intervention.

Most patients with primary pulmonary malignancy die from disease progression or complications during treatment, and MCAO is one of the major complications causing death [4, 5]. Interventional bronchoscopy is gradually being considered a safe procedure and can provide immediate symptomatic relief of dyspnea [14, 24]. In the long-term, primary pulmonary malignancy patients with MCAO treated by bronchoscopic intervention have similar survival rates to those without MCAO [25]. Recent studies have confirmed the safety and efficacy of interventional bronchoscopy, and its role as a treatment modality is expected to increase over time [14, 26]. However, considering the risk of general anesthesia during the procedure, complications, and failure rate around 5%, it is essential to identify the best candidates for interventional bronchoscopy [27, 28].

We investigated the prognostic factors that affect survival after bronchoscopic intervention. First, of the host-related factors, poor performance status and chronic pulmonary disease were associated with poor survival. Patient general health status was reported by previous studies to be a representative factor [13, 27]. As patient performance status decreases, procedure-related complications, such as pneumonia and respiratory distress, may increase, and the opportunity for adjuvant treatment after interventional bronchoscopy may decrease [14]. In addition, smoking status and chronic pulmonary disease were risk factors of complications after bronchoscopic intervention [29]. Therefore, we think poor performance status and chronic pulmonary disease might be independently associated with survival after the first bronchoscopic intervention.

Second, lesion-related factors are degree of extension and type of obstruction at the lesion. In a previous study, patients with single lesion restricted to one lung demonstrated a better survival than those with tracheal obstruction and involvement of both bronchi [30]. Our study showed that extensive lesion was one of the prognostic factors for poor survival. In the case of single lesions, airway patency could be maintained by stenting or other treatment modalities until adjuvant treatments became available. However, in the case of extension lesions, it is possible that the MCAO may recur before adjuvant treatment can begin. The frequency of complications may also increase with repeated obstructions. Endobronchial lesions can be treated by mechanical debulking or laser cautetization, but mixed lesions require multimodality therapy to maintain airway patency [31]. Multimodality therapy often increases the incidence of procedure-related complications and patient mortality [27, 28]. In patients with extrinsic compression, stent insertion is needed to maintain airway patency, but stent placement was one of the risk factors of post-intervention complications and was correlated with poorer survival [27, 32]. In this study, a mixed lesion and extrinsic compression were also prognostic factors of poor survival and could be explained using the reasons described above.

Finally, disease status and adjuvant treatment-related factors are detection time of MCAO and possibility of adjuvant treatment. Many studies have addressed the correlation between additional therapy and survival. Adjuvant treatment after bronchoscopic intervention is
Fig. 1 The overall survival rate of patients after interventional bronchoscopy. Survival rates based on (a) total participants, (b) chronic pulmonary disease, (c) poor performance status, (d) site of the lesion, (e) type of obstruction, and (f) detection time of MCAO and possibility of adjuvant treatment after interventional bronchoscopy. MCAO, malignant central airway obstruction.
known to be associated with a better survival rate [7, 12, 21]. In addition, several studies have explored the impact of previous history of anti-cancer therapy. Jeon et al. demonstrated that newly diagnosed and untreated MCAO patients had a longer survival time following bronchoscopic intervention, and Perin et al. reported that previous chemotherapy was a potential risk factor of intervention-related complications [12, 29]. In contrast, Guibert et al. showed that patients who had been previously treated for MCAO had a better survival rate [13]. Despite these results, Guibert et al. recommended that bronchoscopic intervention should be considered as an early multimodal treatment, not a last action. Because they identified a selection bias among previously untreated patients who received fewer additional treatments after intervention. In our study, patients who were initially diagnosed with MCAO and had undergone adjuvant therapy had the best survival rate among all the patient groups. MCAO caused by disease progression with adjuvant therapy had a similar prognosis as initially diagnosed MCAO without adjuvant therapy. These results suggest that possibility of adjuvant therapy and initial diagnosis are important factors related to survival.

Certain limitations of our study must be acknowledged. First, this was a retrospective study with a single-institution design, which is a source of selection bias. Especially, the proportion of chronic pulmonary disease was reported to 20% in this retrospective study, which is far lower than 30–35% of the largest multicenter cohort study for patients with malignant central airway obstruction [14]. Therefore, the effect of comorbidities may not be properly assessed on the prognosis. Second, treatment options for patients in the terminal stage of primary pulmonary malignancy, such as chemoradiotherapy and supportive care, have advanced over time. These developments might have influenced the slower disease progression and better survival rates of patients in the later study phase compared with those in the earlier study phase. Finally, we were unable to obtain patient spirometric data, quality of life, and symptom scores before and after the bronchoscopic intervention. Most procedures for MCAO patients were provided as palliative therapy, so symptom scores or quality of life assessments might be important factors to consider in this patient population.

Conclusions

In conclusion, bronchoscopic intervention could be a safe and effective procedure for patients with MCAO due to primary pulmonary malignancy. In addition, a poor survival rate was associated with chronic pulmonary disease, poor performance status, extended lesion (vs. single lesion), mixed lesion or extrinsic compression (vs. endobronchial lesion), and MCAO detected as part of the disease progression and/or not receiving adjuvant treatment after the bronchoscopic intervention. This study will help clinicians to determine the best candidates for bronchoscopic intervention among patients with MCAO due to primary pulmonary malignancy.

Abbreviations

aHR: Adjusted hazard ratio; ASA: American Society of Anesthesiologists; CI: Confidence interval; CT: Computed tomography; IQR: Interquartile range; MCAO: Malignant central airway obstruction

Acknowledgements

Not applicable.

Authors’ contributions

BGK and BS have been involved in collection and assembly of data, data analysis and interpretation, and manuscript writing. BC has been involved in collection and assembly of data, data analysis and interpretation, and review. HK has been involved in conception and design and review. BHJ has been involved in conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing, and review. All authors read and approved the final manuscript.

Funding

None.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

This study obtained approval from the institutional review board at Samsung Medical Center (IRB no. 2019-03-002) to review and publish information obtained from patient records. The need for informed consent was waived because patient information was anonymized and de-identified prior to analysis.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, South Korea. 2Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, South Korea. 3Department of Pulmonary and Critical Care Medicine, Kyung Hee University Hospital at Gangdong, School of Medicine, Kyung Hee University, Seoul, South Korea.

Received: 17 May 2019 Accepted: 19 February 2020
Published online: 27 February 2020

References

1. Johnson DH, Schiller JH, Bunn PA Jr. Recent clinical advances in lung cancer management. J Clin Oncol. 2011;29:10(9):737–82.
2. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Management of non-small-cell lung cancer: recent developments. Lancet. 2013;382(9893):709–19.
3. Forde PM, Ettinger DS. Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Rev Anticancer Ther. 2013;13(6):745–58.
4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
